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a  b  s  t  r  a  c  t
Background:  Clinical  data  on  the  mortality  and morbidity  of unselected  Japanese  patients  with  heart  fail-
ure  (HF)  are  limited.  In this  study,  we  aimed  to  determine  the  clinical  characteristics,  long-term  outcomes,
and  prognostic  factors  of Japanese  HF  patients  with preserved  or  reduced  left ventricular  ejection  fraction
(LVEF).
Methods  and  results:  We  used  a single  hospital-based  cohort  from  the  Shinken  Database  2004–2011  that
comprised  all  new  patients  (n =  17,517)  visiting  the  Cardiovascular  Institute  Hospital.  A total  of  1,525
patients  diagnosed  with  symptomatic  HF  at the initial  visit  were  included  in  the  analysis.  Of these,  1121
patients  (74%)  exhibited  a preserved  LVEF  (>50%)  and  404  patients  (26%)  had  a reduced  LVEF  (≤50%).  HF
patients  with  preserved  LVEF  (HFpEF)  were older  and  more  often  female  than  patients  with  reduced  LVEF
(HFrEF).  Kaplan–Meier  curves  and  log-rank  test  results  showed  that  HFpEF  patients  had  a better  prognosis
than  HFrEF  patients.  However,  there  were  no  signiﬁcant  differences  in  clinical  outcomes  between  HFpEF
and  HFrEF  patients  when  the analysis  was  limited  to  inpatients.  Cox regression  analysis  showed  that
HFpEF  patients  had  a signiﬁcantly  lower  risk  of  all-cause  death  (p  =  0.027;  hazard  ratio,  0.547,  95%  conﬁ-
dence  interval,  0.321–0.933).  Multivariate  analyses  performed  separately  showed  that  the  independent
predictors  of all-cause  death  in HFrEF  were  advanced  age,  lower  body  mass  index,  diabetes  mellitus,  and
the  absence  of  statin  treatment,  whereas  those  for HFpEF  were  advanced  age,  absence  of dyslipidemia,
anemia,  and left  ventricular  hypertrophy.
Conclusions: This  prospective  cohort  study  identiﬁed  the  clinical  characteristics,  long-term  outcomes,  and
prognostic  factors  of  Japanese  HF  patients  with  reduced  and  preserved  ejection  fractions  in a  real-world
clinical  setting.
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In Japan’s rapidly aging population, heart failure (HF) has
ecome a common and deteriorating condition [1]. In addition to
he increased prevalence of HF, HF with a preserved ejection frac-
ion (HFpEF) is increasingly being recognized as a public health
roblem. The prevalence of HFpEF is similar to that of HF with
educed ejection fraction (HFrEF). HFpEF is associated with poor
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clinical outcomes, which are believed to be slightly better than
those of HFrEF.
The  epidemiology of HF in Japan is different from that in Western
countries with respect to ethnic background and etiology. However,
there are few Japanese hospital-based reports about preserved
left ventricular ejection fraction (LVEF) [2–4], and the prevalence
and prognosis of HF with preserved LVEF are not well known.
Tsuchihashi-Makaya et al. examined patients from the Japanese
Cardiac Registry of Heart Failure in Cardiology who were hospi-
talized for HF and demonstrated that patients with HFpEF had
similar mortality rates and equally high rates of rehospitalization as
those with HFrEF [4]. However, the patients enrolled in these stud-
ies had severe HF that required hospitalization. To our knowledge,
the differences in clinical characteristics, outcomes, and prognostic
factors between patients with HFpEF and those with HFrEF in an
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nselected Japanese HF population that includes both inpatients
nd outpatients with mild symptoms have not been examined.
herefore, we examined a hospital-based cohort from the Shinken
atabase using data obtained between 2004 and 2011. The registry
as initiated in 2004, and patients have since been continually reg-
stered to the database annually. In the present study, we aimed
o clarify the differences in clinical characteristics, outcomes, and
rognostic factors between patients with HFpEF and those with




The  Shinken Database includes all patients (inpatients and out-
atients) who were examined at the Cardiovascular Institute in
okyo, Japan (“Shinken” is a Japanese abbreviation for the name
f the hospital), and excludes patients who are foreign travelers
nd those with active cancer. This hospital-based database was
stablished to investigate the prevalence and prognosis of cardio-
ascular diseases in the urban areas of Japan [5,6]. The registry
egan in June 2004, and patients have been continually registered
o the database annually. The present study analyzed data from this
atabase collected between June 2004 and March 2012 (Shinken
atabase 2004–2011) and included 17,517 new visiting patients.
n the present study, HF patients were deﬁned as those with symp-
omatic HF [New York Heart Association (NYHA) classes II–IV]
oexistent with structural heart diseases, which were diagnosed
sing cardiovascular diagnostic tests such as echocardiography,
uclear scanning, and angiography. We  deﬁned HFpEF patients as
hose with symptomatic HF and preserved LVEF (i.e. LVEF > 50%),
nd HFrEF patients as those with symptomatic HF and reduced LVEF
i.e. LVEF ≤ 50%), as previously described [7]. We  excluded patients
ith valvular heart disease. Valvular heart disease was deﬁned as
ong-standing mitral or aortic valve involvement as documented by
hysical examination and echocardiography, angiography, or his-
ory of surgical repair. We  deﬁned inpatients as patients who were
dmitted to or transferred to our hospital because of HF (not for
xamination) at their ﬁrst hospital visit, whereas outpatients are
atients who have symptomatic HF and visited the outpatient clinic
f our hospital without hospital admission at their ﬁrst hospital
isit.
thics
The ethical committee of the Cardiovascular Institute approved
his study, and all the patients provided written informed consent.
ata collection
For  each patient, after undergoing electrocardiography and
hest radiography, cardiovascular status was evaluated by echocar-
iography, an exercise test, 24-h Holter recordings, and blood
aboratory data as prescribed by the attending physician within 3
onths after the ﬁrst visit. As initial clinical parameters, collected
ata included gender, age, body mass index (BMI), drug infor-
ation, and coexisting conditions, including hypertension, atrial
brillation, diabetes mellitus, and dyslipidemia. In most patients,
dditional echocardiographic parameters included left ventricular
iameter of the diastole (LVDd), left ventricular diameter of the
ystole (LVDs), interventricular septum thickness (IVST), posterior
all thickness (PWT), and LVEF using M-mode echocardiography.
eft ventricular (LV) hypertrophy was deﬁned by echocardiogra-
hy (IVST or PWT  ≥ 13 mm).  Anemia was deﬁned as a hemoglobin
evel of <11 g/dL. An estimated glomerular ﬁltration rate (eGFR)iology 62 (2013) 102–109 103
was  calculated using the eGFR equation for the Japanese popula-
tion: eGFR = 194 × (serum creatinine)−1.094 × (age)−0.287 × (0.739, if
the patient is female) [8]. A baseline eGFR < 60 mL min−1·1.73 m−2
was used for deﬁning chronic kidney disease (CKD) [9]. Idiopathic
dilated cardiomyopathy was diagnosed by the presence of global
LV dilatation with impaired systolic function occurring in the
absence of known cardiac causes. Hypertrophic cardiomyopathy
was diagnosed by echocardiography when hypertrophy (IWST or
PWT  > 12 mm)  without hypertension was present. We  conﬁrmed
the deaths of study patients by the medical records of our hospi-
tal or by the information obtained during follow-up. We  deﬁned
cardiovascular death as death resulting from acute myocardial
infarction, sudden cardiac death, death due to heart failure, death
due to stroke, or death due to other cardiovascular causes. HF
admission was  deﬁned as exacerbation of chronic HF requiring
hospitalization and was determined by the outpatient clinic physi-
cian according to the presenting symptoms, physical examination
results, laboratory data, and chest radiography ﬁndings.
Patient follow-up
The  health status and incidence of cardiovascular events and
mortality of patients are maintained in the database by linking to
the medical records of the hospital and through study documents
that were sent once per year to those who stopped hospital visits
or who were referred to other hospitals.
We excluded the follow-up data obtained after April 1, 2012,
from data analysis. Therefore, the end of the follow-up period was
deﬁned as one of the following: (1) the date of death, if the date
was before March 31, 2012; (2) the ﬁnal hospital visit or the ﬁnal
response to our study documents involving prognosis with conﬁr-
mation of being alive before March 31, 2012; (3) March 31, 2012,
when the date of death, the ﬁnal hospital visit, or the ﬁnal response
to our study documents involving prognosis were later than
April 1, 2012.
Statistical analysis
Categorical and consecutive data regarding patient background
are presented as numbers (%) and means ± standard deviation,
respectively. The chi-square test was  used for comparisons
between groups, and the unpaired t-test was used for compari-
son of consecutive variables. Long-term, event-free survival was
estimated using Kaplan–Meier curves and the log-rank test to
assess the signiﬁcance of differences between the 2 groups. Cox
regression analysis was used to identify the effects of HFpEF on
long-term clinical outcomes. Univariate Cox regression analysis
was used to identify the co-factors with signiﬁcant effects on all-
cause mortality. Step-wise multivariate Cox regression analysis
was performed to determine the independent prognostic factors
for all-cause death. For subanalysis, patients with HF were seg-
regated into outpatients and inpatients. Clinical outcomes were
compared between patients with HFpEF and HFrEF in the outpa-
tient and inpatient groups, respectively. A probability value of <0.05
was considered to indicate a statistically signiﬁcant difference. Sta-
tistical analyses were performed using SPSS (SPSS Inc., Chicago,
IL, USA), version 19.0 software.
Results
Patient characteristicsOf  the 17,517 patients who had visited our hospital, 1,525
patients were diagnosed with symptomatic HF without valvular
heart disease. These patients were followed for an average period
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,121 patients, 74%) and HFrEF (LVEF ≤ 50%; 404 patients, 26%).
here were 1,330 outpatients (HFpEF: 1,048 patients, 79%; HFrEF:
82 patients, 21%), and 195 inpatients (HFpEF: 73 patients, 37%;
FrEF: 122 patients, 63%). Compared with patients with HFrEF,
atients with HFpEF were older, more often female, less likely to
ave diabetes mellitus, hyperuricemia, CKD, anemia, a prior his-
ory of myocardial infarction, dilated cardiomyopathy, or atrial
brillation, and had a higher rate of dyslipidemia. Ultrasound
ardiography results showed that IVST, PWT, LVDd, and LVDs
ere greater in HFrEF patients than in HFpEF patients. LVEF
nd left ventricular fractional shortening were greater in HFpEF
atients than in HFrEF patients. The mean B-type natriuretic pep-
ide (BNP) level was signiﬁcantly lower in patients with preserved
VEF than in those with reduced LVEF. The use of beta-blockers,
enin–angiotensin-system inhibitors (RAS-Is), diuretics, and dig-
talis was more common among HFrEF patients, whereas use of
alcium channel blockers, statins, and nitrates was more common
n HFpEF patients. The HFpEF group had a higher prevalence of
YHA II, but a lower prevalence of NYHA III and IV heart failure
han the HFrEF group (Table 1).
able 1
haracteristics of patients.
HFrEF (n = 404) HFpEF (n = 1,121) p-Value
Age (years) 63.0 ± 13.8 65.6 ± 11.7 <.001
Male sex 81.2 76.2 .039
BMI  (kg/m2) 24.6 ± 4.8 24.3 ± 3.6 .209
Hypertension 59.9 64.5 .100
Dyslipidemia 51.7 66.8 <.001
Diabetes mellitus 39.9 32.4 .007
Hyperuricemia 19.6 11.4 <.001
Cigarette 28.6 24.2 .144
CKD 46.5 27.6 <.001
Anemia 14.3 9.7 .013
Prior MI  26.2 9.6 <.001
DCM 24.5 0.4 <.001
HCM 2.0 3.9 .065
AF 19.3 9.0 <.001
BNP (pg/mL) 671.0 ± 772.7 232.6 ± 460.5 <.001
UCG
IVST (mm) 9.4 ± 2.2 10.0 ± 2.2 <.001
PWT (mm)  8.7 ± 1.8 9.1 ± 1.5 <.001
LVDd (mm)  57.3 ± 8.6 46.0 ± 4.6 <.001
LVDs (mm)  48.0 ± 9.9 28.9 ± 4.7 <.001
LVFS (%) 16.7 ± 6.2 37.4 ± 5.8 <.001
LVEF (%) 34.0 ± 11.7 67.0 ± 7.5 <.001
LVH 8.6 9.7 .542
NYHA class
II  55.4 78.6 <.001
III 23.8 15.7 <.001
IV 20.8 5.7 <.001
Medications
Beta-blockers 55.0 37.7 <.001
Calcium channel blockers 19.1 30.5 <.001
ACE-Is 27.7 13.4 <.001
ARBs 49.8 34.9 <.001
RAS-Is 71.0 44.8 <.001
Statins 43.6 54.9 <.001
Diuretics 63.6 19.1 <.001
Digitalis 15.6 3.4 <.001
Nitrate 39.6 60.8 <.001
FrEF, heart failure with reduced left ventricular ejection fraction; HFpEF, heart
ailure with preserved left ventricular ejection fraction; BMI; body mass index;
KD,  chronic kidney disease; IHC, ischemic heart disease; prior MI,  prior history
f  myocardial infarction; DCM, idiopathic dilated cardiomyopathy; HCM, hyper-
rophic cardiomyopathy; AF, atrial ﬁbrillation; BNP, brain natriuretic peptide; UCG,
ltrasound cardiography; IVST, interventricular septum thickness; PWT, posterior
all thickness; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular
nd-systolic dimension; LVFS, left ventricular fractional shortening; LVEF, left ven-
ricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart
ssociation; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II
eceptor blocker; RAS-I, renin–angiotensin system inhibitor. Data are expressed as
ean ± standard deviation, or percentage.iology 62 (2013) 102–109
Clinical outcomes
All-cause death occurred in 4.5% of patients in the HFpEF group,
and 11.4% of patients in the HFrEF group. Cardiovascular death (HF
death) occurred in 1.7% (0.8%) of the patients in the HFpEF group,
and 5.2% (2.0%) of the patients in the HFrEF group. Admission for
HF occurred in 4.1% of the patients with HFpEF and 15.8% of the
patients with HFrEF (Table 2). Kaplan–Meier curves and log-rank
test results showed that frequency of all-cause death, cardiovascu-
lar death, HF death, and HF admission, were signiﬁcantly higher in
HFrEF patients than in HFpEF patients (Fig. 1).
Cox regression analysis showed that HFpEF was  associated
with a lower incidence of all-cause death [p < 0.001; hazard ratio
(HR) 0.369, 95% conﬁdence interval (95% CI) 0.247–0.549], car-
diovascular death (p < 0.001; HR 0.307, 95% CI 0.165–0.571), and
HF admission (p < 0.001; HR 0.222, 95% CI 0.152–0.324). The
Cox regression model was used in the analysis to adjust for
the following covariates: age, sex, dyslipidemia, diabetes mel-
litus, hyperuricemia, CKD, anemia, prior history of myocardial
infarction, dilated cardiomyopathy, atrial ﬁbrillation, BNP level,
LVEF, NYHA III/IV, beta blockers, calcium channel blockers, RAS-
Is, statins, diuretics, digitalis, and nitrate. It showed that patients
with HFpEF had a comparable risk for cardiovascular death
(p = 0.436; HR 0.730, 95% CI 0.331–1.611), HF death (p = 0.452,
HR 0.626, 95% CI 0.184–2.126), and HF admission (p = 0.360, HR
1.456, 95% CI 0.652–3.237), but had a signiﬁcantly lower risk
for all-cause death (p = 0.027, HR 0.547, 95% CI 0.321–0.933)
(Table 3).
Predictors for all-cause death
Univariate Cox regression analysis showed that age, BMI, dys-
lipidemia, diabetes mellitus, cigarette smoking, CKD, anemia,
statins, and BNP level were associated with all-cause death in
HF with HFrEF (Table 4). Multivariate Cox regression analysis,
including the signiﬁcant predictors identiﬁed in the univariate
model, showed that older age, lower BMI, diabetes mellitus, and
the absence of statin treatment were independent predictors
of all-cause death in HFrEF (Table 4). Univariate Cox regres-
sion analysis showed that age, BMI, dyslipidemia, hyperuricemia,
CKD, anemia, AF, statins, diuretics, NYHA III/IV, BNP level, and
LV hypertrophy were associated with all-cause death in HFpEF
(Table 5). Multivariate Cox regression analysis, including the sig-
niﬁcant predictors, identiﬁed in the univariate model showed that
advanced age, absence of dyslipidemia, anemia, and LV hyper-
trophy were independent predictors of all-cause death in HFpEF
(Table 5).
SubanalysisKaplan–Meier curves and the log-rank test results revealed that
the frequencies of all-cause death, cardiovascular death, HF death,
and HF admission were signiﬁcantly higher in HFrEF than in HFpEF
Table 2
Clinical outcomes.
HFrEF (n = 404) HFpEF (n = 1,121) p-Value
All-cause death 11.4 4.5 <.001
Heart failure death 2.0 0.8 .053
Cardiovascular death 5.2 1.7 <.001
Heart failure admission 15.8 4.1 <.001
HFrEF, heart failure with reduced left ventricular ejection fraction; HFpEF, heart
failure with preserved left ventricular ejection fraction. Data are expressed as per-
centage.
H. Kaneko et al. / Journal of Cardiology 62 (2013) 102–109 105









(dmission-free survival rate (D). HFpEF, heart failure patients with preserved left 
jection fraction.
utpatients (Fig. 2), whereas these were all comparable among
npatients (Fig. 3).
iscussion
The  present study analyzed data from an observational cohort
f HF patients to determine the mortality and morbidity of unselec-
ed Japanese HF patients in a real-world clinical setting. The major
ndings of the present study were as follows:1) HFpEF was present in approximately 74% of all of the HF inpa-
tients  (37%) and outpatients (79%) visiting a cardiovascular
hospital in Japan.cular ejection fraction; HFrEF, heart failure patients with reduced left ventricular
(2)  Patients with HFpEF showed a better prognosis than those with
HFrEF.  However, our sub-analysis showed that among inpa-
tients,  the clinical outcomes of HFpEF and HFrEF patients were
comparable.
(3) In HFrEF, older age, lower BMI, diabetes mellitus, and the
absence  of statin treatment were independent predictors of
all-cause  death, whereas older age, absence of dyslipidemia,
anemia, and LV hypertrophy were independent predictors of
all-cause  death in HFpEF.The prevalence of HFpEF, which has increased with time in
Western countries [10], varies according to age, race, and the cutoff
value for LVEF. Nevertheless, there is widespread agreement that
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Table 3
Hazard ratios of clinical outcomes of patients with HFpEF.
p-Value Hazard ratio 95% CI
All-cause death
Unadjusted HR <.001 .369 .247–.549
Adjusted HR .027 .547 .321–.933
Cardiovascular death
Unadjusted  HR <0.001 .307 .165–.571
Adjusted HR .436 .730 .331–1.611
HF death
Unadjusted HR .054 .392 .151–1.016
Adjusted HR .452 .626 .184–2.126
HF admission
Unadjusted HR <.001 .222 .152–.324
Adjusted HR .360 1.456 .652–3.237






















Predictors for death in HFpEF.
p-Value Hazard ratio 95% CI
Univariate
Age <.001 1.117 1.085–1.149
Male .062 .574 .320–1.028
BMI <.000 .812 .736–.895
Hypertension .667 1.134 .638–2.017
Dyslipidemia <.001 .304 .172–.536
Diabetes mellitus .274 1.366 .782–2.385
Hyperuricemia .041 2.057 1.030–4.110
Cigarette .660 .828 .356–1.922
CKD <.001 4.130 2.357–7.237
Anemia <.001 10.745 6.109–18.896
Prior MI .452 .676 .243–1.877
DCM .855 .050 .000–4.596
HCM .415 .047 .000–72.407
AF .013 2.491 1.212–5.121
Beta-blockers .759 .913 .521–1.609
Calcium channel blockers .762 1.094 .611–1.959
RAS-Is .705 1.112 .642–1.926
Statins <.001 .259 .140–.479
Diuretics <.001 2.798 1.569–4.990
Nitrate .937 .977 .550–1.737
NYHA III or IV <.001 3.918 2.257–6.802
BNP <.001 1.001 1.001–1.001
LVH <.001 4.200 2.181–8.089
LVEF .064 .966 .932–1.002
Multivariate
Age .001 1.076 1.030–1.125
Dyslipidemia .041 .445 .204–.969
Anemia <.001 5.527 2.450–12.466atio; CI, conﬁdence interval; HF, heart failure.
FpEF is noted in more than one-third of all patients admitted with
F [2,11–20]. A recent study conducted by Tsuchihashi-Makaya
t al. reported that HFpEF is present in one-third of all admit-
ed HF patients [4]. In our study, the prevalence of HFpEF was
2%, which was signiﬁcantly higher than that of previous reports
n both Western countries and Japan. This could be attributed
o the HF outpatients that were included in our cohort. In fact,
0% of the inpatients with HF had preserved LVEF, which was
n agreement with the ﬁndings of previous studies. The high
revalence of HFpEF suggests that this type of HF merits further
ttention.
able 4
redictors for death in HFrEF.
p-Value Hazard ratio 95% CI
Univariate
Age <.001 1.065 1.039–1.092
Male .790 1.116 .499–2.495
BMI .001 .863 .791–.942
Hypertension .537 .833 .466–1.489
Dyslipidemia .018 .480 .262–.881
Diabetes mellitus .006 2.275 1.265–4.092
Hyperuricemia .094 .416 .149–1.162
Cigarette .006 .133 .032–.552
CKD <.001 4.436 2.250–8.743
Anemia <.001 4.271 2.345–7.782
Prior MI  .148 1.565 .853–2.872
DCM .475 .767 .370–1.589
HCM .236 2.357 .571–9.728
AF .571 .792 .354–1.772
Beta-blockers .299 .736 .413–1.313
Calcium channel blockers .507 1.258 .639–2.478
RAS-Is .151 .641 .349–1.177
Statins .002 .337 .167–.679
Diuretics .700 .890 .492–1.610
Nitrate .483 1.231 .689–2.200
NYHA III/IV .143 1.541 .564–2.748
BNP <.001 1.001 1.000–1.001
LVH .211 1.733 .732–4.101
LVEF .298 .987 .964–1.011
Multivariate
Age .011 1.052 1.012–1.095
BMI .024 .852 .741–.980
DM .006 3.504 1.431–8.578
Statin .019 .323 .125–.831
MI, body mass index; CKD, chronic kidney disease; IHD, ischemic heart dis-
ase;  prior MI,  prior history of myocardial infarction; DCM, idiopathic dilated
ardiomyopathy;  HCM, hypertrophic cardiomyopathy; AF, atrial ﬁbrillation; RAS-I,
enin–angiotensin system inhibitor; NYHA, New York Heart Association; BNP, brain
atriuretic peptide; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection
raction; DM,  diabetes mellitus. CI, conﬁdence interval.
LVH .018 2.820 1.192–6.672
BMI, body mass index; CKD, chronic kidney disease; IHD, ischemic heart dis-
ease;  prior MI,  prior history of myocardial infarction; DCM, idiopathic dilated
cardiomyopathy;  HCM, hypertrophic cardiomyopathy; AF, atrial ﬁbrillation; RAS-I,
renin–angiotensin system inhibitor; NYHA, New York Heart Association; BNP, brain
natriuretic peptide; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection
fraction. CI, conﬁdence interval.
Patients with HFpEF are older, more often female, and more
frequently have hypertension compared to patients with HFrEF
[2,11,12,16–21]. Similar background differences were demon-
strated in Japanese HF patients in both inpatient-based and
community-based cohorts [3,4]. The differences in patients’ back-
grounds in our study were almost identical to those of previous
reports, and patients with HFpEF were older and more often
female.
Whether the long-term clinical outcomes of HFpEF and HFrEF
patients differ is not clear. Smith et al. and Solomon et al. reported
that patients with HFpEF had a signiﬁcantly better prognosis than
those with HFrEF [19,22]. However, no signiﬁcant differences in
mortality between patients with preserved and reduced LVEF were
reported by other studies [11,12,23]. Previous studies conducted
in Japan found no signiﬁcant differences in prognosis between 3
groups divided on the basis of LVEF [2,4]. In the present study,
patients with HFpEF had a signiﬁcantly better prognosis than those
with HFrEF. Interestingly, no signiﬁcant differences in clinical out-
comes between HFpEF and HFrEF patients were detected when
the analysis was limited to inpatients. This was  in agreement with
the results of previous studies [2,4,11,12,23] that included hospi-
talized HF patients and showed that the prognoses of HFpEF and
HFrEF were comparable. On the other hand, Solomon et al. reported
that LVEF was a powerful predictor of cardiovascular outcome in
a broad spectrum of patients with HF, including outpatients and
inpatients [22]. The ﬁndings of this study suggested that although
patients with HFpEF generally had favorable outcomes, the prog-
nosis of HFpEF does not differ from that of HFrEF in patients with
decompensated HF requiring hospital admission.
Previous studies identiﬁed the prognostic factors for HF, includ-
ing older age, the severity of HF [24,25], anemia [26], the presence
H. Kaneko et al. / Journal of Cardiology 62 (2013) 102–109 107
Figure 2. Kaplan–Meier curves for all-cause death-free survival rate (A), cardiovascular death-free survival rate (B), heart failure death-free survival rate (C), and heart failure














Lf CKD [27–29] and lower LVEF [30]. However, whether these
redictors could be applied to both preserved and reduced LVEF
emained unclear. In the present study, multivariate analyses
emonstrated that the independent predictors of all-cause death
n HFrEF were older age, lower BMI, diabetes mellitus, and the
bsence of statin treatment, whereas, older age, the absence of
yslipidemia, anemia, and LV hypertrophy were independent pre-
ictors of all-cause death in HFpEF. Hence, older age was  a common
isk factor of reduced and preserved LVEF. On the other hand, the
ffect of other factors differed between the reduced and preserved
VEF groups. Therefore, our results underscore that different factors
hould be paid more attention to, according to reduced or preserved
VEF.Study limitations
The  present study had several limitations. First, this study
was a single center-based study. Because our hospital is a single-
department cardiovascular facility, the results of this study cannot
be generalized to all medical centers. Second, the deﬁnition of
HFrEF and HFpEF in the present study was based on LVEF, and
it therefore remains unknown whether the study population
had objective evidence of diastolic dysfunction, as deﬁned by
guidelines for the diagnosis of HFpEF [12]. Third, the propor-
tion of patients treated with drugs known to be effective for the
treatment of HF was lower in the present study than in other
studies.

















pigure 3. Kaplan–Meier curves for all-cause death-free survival rate (A), cardiovascu
dmission-free survival rate (D). HFpEF, heart failure patients with preserved left 
jection fraction.
onclusion
The present study analyzed an observational cohort of Japanese
atients with HF to determine the real-world clinical character-
stics and long-term mortality and morbidity of HF with respect
o HFpEF and HFrEF status. Long-term clinical outcomes were
etter in patients with HFpEF than in those with HFrEF. Interest-
ngly, no signiﬁcant differences in clinical outcomes between HFpEF
nd HFrEF patients were detected when the analysis was  limited
o inpatients. Multivariate analysis showed that older age, lower
MI, diabetes mellitus, and the absence of statin treatment were
he independent predictors of all-cause death in HFrEF patients,
hereas older age, absence of dyslipidemia, anemia, and LV hyper-
rophy were the independent predictors of all-cause death in HFpEF
atients—suggesting that various factors should be considered for
reserved or reduced LVEF.ath-free survival rate (B), heart failure death-free survival rate (C), and heart failure
cular ejection fraction; HFrEF, heart failure patients with reduced left ventricular
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